(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 6.23% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Astrazeneca's revenue in 2025 is $54,073,000,000.On average, 5 Wall Street analysts forecast AZN's revenue for 2025 to be $89,074,009,614,267, with the lowest AZN revenue forecast at $88,235,384,276,534, and the highest AZN revenue forecast at $90,400,711,245,474. On average, 5 Wall Street analysts forecast AZN's revenue for 2026 to be $94,774,073,428,960, with the lowest AZN revenue forecast at $92,947,556,318,705, and the highest AZN revenue forecast at $97,058,719,582,630.
In 2027, AZN is forecast to generate $100,513,148,987,027 in revenue, with the lowest revenue forecast at $98,865,107,501,611 and the highest revenue forecast at $103,803,760,080,181.